Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

REDWOOD CITY, Calif., November 05, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at $106.53.

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. These figures are ...

Baron Health Care Fund highlighted stocks like Arcellx, Inc. (NASDAQ:ACLX) in its Q3 2024 investor letter. Headquartered in Redwood City, California, Arcellx, Inc. (NASDAQ:ACLX) engages in the ...

Arcellx (ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for anito-cel in ...

Arcellx, Inc. (ACLX) shares rallied 6.7% in the last trading session to close at $92.98. This move can be attributable to notable volume with a higher number of shares being traded than in a ...